Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-61815 vs Tolvaptan in Congestive Heart Failure
NCT03772041Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Primary completion
- Jul 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tolvaptan sodium phosphate in heart failure (HF), sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Jan 2019; status: completed.
02
Drugs
tolvaptan sodium phosphate
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03772041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772041.